Today, we are celebrating a series of groundbreaking advancements that mark the start of a new era for Discovery. The official opening of our brand-new state-of-the-art facilities in Huntsville, AL, and Alameda, CA, the launch of revolutionary Olink Explore HT services, and our revitalized website together will amplify our ability to empower scientists on a global scale. "This trifecta of advancements signifies a profound moment in our journey," said Discovery CEO Glenn Bilawsky. "From Alameda to Huntsville, from the physical to the digital, we're reshaping the future of life sciences. We're more equipped than ever to catalyze innovations that have the potential to transform lives." - Glenn Bilawsky, CEO of Discovery Life Sciences Visit our new website to learn more: https://lnkd.in/gHr-CZZ2
Discovery Life Sciences
Biotechnology Research
Huntsville, Alabama 20,569 followers
Science at your Service™
About us
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Our robust biospecimen and biomarker platform is optimized for speed and large scale capacity. We routinely manage hundreds of studies and expertly test thousands of biospecimens simultaneously as a single vendor - eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish. Leading biopharma, diagnostic and academic institutions trust us to quickly deliver high-quality biospecimens and reliable, reproducible biomarker data, so they can outpace their competition and push the leading edge of innovation. Visit www.dls.com to learn more
- Website
-
http://www.dls.com
External link for Discovery Life Sciences
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Huntsville, Alabama
- Type
- Privately Held
- Founded
- 2018
- Specialties
- human clinical samples, cancer tissues, primary cells, peripheral blood mononuclear cells, bone marrow mononuclear cells, whole blood, circulating tumor cells, lab services, blood processing, histology, pathology, protocol development, assay development, clinical targeting, sample pre-screening, data security, analytical services, tissue analysis, molecular testing, flow cytometry analysis, sample validation, quality control, genomic services, and Next-Gen Sequencing
Locations
Employees at Discovery Life Sciences
Updates
-
Don't miss the presentation during CAR-TCR on Day 1: Wed, Sep 18, 12:05 pm. We look forward to another great show in Boston!
Will you be attending the CAR-TCR Summit next week in Boston? Yuki Kato Maves, PhD, of Discovery Life Sciences will be talking about PBMC isolation in GMP manufacturing workflow in the Supply chain & Clinical Operations Track on Day 1 Wed, Sep 18, 12:05 pm. Mark your calendar to attend this presentation. We are excited to meet you next week. Connect with the team: McLean Collins, Angela Martinovic, Karen Bostwick, Conor Marino, Andy L. Chiang Click here to schedule a private meeting with us: https://lnkd.in/gUCZyZCt We look forward to seeing you!
-
We look forward to meeting you at #ESMO2024. Stop by Booth #338 to discuss more about Discovery’s biospecimen and specialty lab service capabilities and learn more about our works in both preclinical research and clinical trials. Schedule a private meeting: https://lnkd.in/g8jkU7EM Connect with the team: Oliver Lehner, Jon Beck, FRCPath, Oliver Stoss, Riem Adjam, T. Scott Reid, Andreas Rossbach, Preeti Panda, Marta Prats Lopez, Anastas Patarinski, Zhenda Lazarova, Yulia Skorokhod, Jessica Kornke
-
Discovery is now offering tumoroids! Introducing Tumoroid Cell Lines, OncoPro™ Medium-Derived. Also known as cancer organoids, tumoroids are patient-derived cancer cells grown as 3D, self-organized multicellular structures. They can be used for drug screening and testing, biomarker identification, drug response testing, drug dose and concentration studies, and more. These culture-ready tumoroid cell lines, alongside our matched biospecimens including DTCs, PBMCs, and FFPE tissue samples, enable oncology researchers to unlock deeper insights into tumor biology, understand disease mechanisms, and identify potential therapeutic targets. Learn more: https://lnkd.in/gwZSSpFJ Discovery’s cell biology service lab also offers a suite of tumoroid add-on services that can generate physiologically relevant, multidimensional data. Speak with our biospecimen specialist today: https://lnkd.in/gE-9h74n #Tumoroids #CancerOrganoids #Oncology Note: OncoPro™ is a trademark of Thermo Fisher Scientific and its subsidiaries. These products are for research use only, not for use in diagnostic procedures.
-
The Alliance for Regenerative Medicine’s August 2024 Sector Snapshot focuses on "The Emerging Value of Cell and Gene Therapy." While discussions often center on the high cost of CGTs, their true value—both to patients and society—is frequently overlooked. In-depth analysis reveals that CGTs outperform the current standard of care, and as a result, deliver substantial savings back to the healthcare system. By reducing long-term costs and improving patient outcomes, CGTs contribute to a more sustainable healthcare system. Read more: https://lnkd.in/eX2TJiYf AllCells, a Discovery Life Sciences CGT brand, specializes in leukapheresis and custom prospective collections of high-quality CGT starting materials. AllCells® RUO and GMP products have supported many complex programs transition seamless from early discovery to process development and manufacturing: www.allcells.com. #CellTherapy #GeneTherapy #Immunotherapy #RegenerativeMedicine
The Sector Snapshot: August 2024 - Alliance for Regenerative Medicine
https://alliancerm.org
-
Meet with our cell and gene therapy team next week at CAR-TCR!
Join our CGT team at Booth 38 during the 9th Annual CAR-TCR Summit. Our team is excited to be back in Boston from September 17-19 at the Hynes Convention Center. Connect with the team: McLean Collins Yuki Kato Maves, PhD Angela Martinovic Karen Bostwick Conor Marino Andy L. Chiang Click here to schedule a private meeting with us: https://lnkd.in/gUCZyZCt We look forward to seeing you! #CARTCR #immunotherapy #celltherapy #celltherapies #immunology
-
Planning to attend ISSX/JSSX meeting in Honolulu? Come visit Discovery Life Sciences at Booth #113 and meet with our in vitro ADMET experts Dr. Albert Li and Dr. Feng Li. Dr. Li and Dr. Li will also be hosting a breakfast symposium on Day 2, Sep 17, 7:15-8:13am. Title: Recent Advances in Human Hepatocyte Technologies for Drug Discovery & Development Make sure to mark your calendar. We look forward to seeing you! More info: https://lnkd.in/gn6qw4Xa
-
Join us at #ESMO2024 in Barcelona from 13-17 September and meet with Discovery’s team of biospecimens and specialty lab services experts. Visit us at Booth #338 to discuss your ongoing and future project. Schedule a private meeting: https://lnkd.in/g8jkU7EM We look forward to connecting with you!
-
It’s estimated that every 3 minutes, someone in the US is diagnosed with a form of blood cancer. Leukemia and lymphoma alone represent 80% of all new cases: https://lnkd.in/emuArfjg Discovery is committed to supporting oncology research and providing starting cellular materials for cell and gene therapies, which are setting new therapeutic benchmarks for leukemias and lymphomas. Join us in advancing the fight against blood cancers and making a difference in patients' lives. #BloodCancerAwarenessMonth #Leukemia #Lymphoma #Oncology
-
Sacituzumab Govitecan (SG), an antibody-drug conjugate (ADC) approved for breast cancer, shows promise in treating brain metastases from breast cancer (BCBM) and recurrent glioblastoma (rGBM), according to results from a prospective trial at the University of Texas Health Science Center at San Antonio. Read more: https://lnkd.in/g5S_Zv9p ADC therapy is a revolutionary approach designed to target specific tumor cells with high precision while minimizing toxicity to healthy cells. Discovery has helped many ADC therapy developers adopt robust, sensitive, and clinical trial ready assays: https://lnkd.in/gA7nHFxD Discovery’s cell biology experts are also experienced in assessing off-target toxicity and linker stability for potential ADC therapies: https://lnkd.in/gUqjFDpw Speak with our ADC experts today. #CancerResearch #ADC #BreastCancer #Glioblastoma
Breast Cancer’s Spread to Brain Could Be Treated by Antibody-Drug Conjugate
genengnews.com